Generali Investments Management Co LLC Acquires 3,281 Shares of Eli Lilly and Company $LLY

Generali Investments Management Co LLC lifted its holdings in Eli Lilly and Company (NYSE:LLY) by 35.3% during the third quarter, HoldingsChannel.com reports. The institutional investor owned 12,567 shares of the company’s stock after buying an additional 3,281 shares during the period. Eli Lilly and Company makes up about 2.0% of Generali Investments Management Co LLC’s portfolio, making the stock its 12th biggest holding. Generali Investments Management Co LLC’s holdings in Eli Lilly and Company were worth $9,589,000 at the end of the most recent quarter.

Other hedge funds have also recently made changes to their positions in the company. Brighton Jones LLC increased its position in shares of Eli Lilly and Company by 22.0% during the 4th quarter. Brighton Jones LLC now owns 9,597 shares of the company’s stock valued at $7,409,000 after purchasing an additional 1,730 shares during the last quarter. Revolve Wealth Partners LLC boosted its stake in Eli Lilly and Company by 2.8% during the fourth quarter. Revolve Wealth Partners LLC now owns 1,471 shares of the company’s stock worth $1,136,000 after buying an additional 40 shares during the period. OneAscent Wealth Management LLC boosted its stake in Eli Lilly and Company by 32.0% during the second quarter. OneAscent Wealth Management LLC now owns 359 shares of the company’s stock worth $280,000 after buying an additional 87 shares during the period. Sequoia Financial Advisors LLC increased its position in Eli Lilly and Company by 19.0% during the second quarter. Sequoia Financial Advisors LLC now owns 140,201 shares of the company’s stock valued at $109,291,000 after acquiring an additional 22,410 shares during the last quarter. Finally, Schnieders Capital Management LLC. raised its stake in shares of Eli Lilly and Company by 16.7% in the second quarter. Schnieders Capital Management LLC. now owns 7,993 shares of the company’s stock valued at $6,231,000 after acquiring an additional 1,141 shares during the period. 82.53% of the stock is currently owned by hedge funds and other institutional investors.

Eli Lilly and Company Stock Performance

Shares of NYSE:LLY opened at $1,022.16 on Friday. The firm’s 50 day simple moving average is $1,053.57 and its 200-day simple moving average is $925.14. The company has a debt-to-equity ratio of 1.54, a quick ratio of 1.19 and a current ratio of 1.58. Eli Lilly and Company has a one year low of $623.78 and a one year high of $1,133.95. The firm has a market cap of $964.26 billion, a PE ratio of 44.54, a price-to-earnings-growth ratio of 1.20 and a beta of 0.39.

Eli Lilly and Company (NYSE:LLY) last announced its quarterly earnings data on Wednesday, February 4th. The company reported $7.54 earnings per share (EPS) for the quarter, topping the consensus estimate of $7.48 by $0.06. The company had revenue of $19.29 billion for the quarter, compared to analysts’ expectations of $17.85 billion. Eli Lilly and Company had a return on equity of 102.94% and a net margin of 31.66%.Eli Lilly and Company’s revenue was up 42.6% compared to the same quarter last year. During the same quarter in the prior year, the firm earned $5.32 earnings per share. Eli Lilly and Company has set its FY 2026 guidance at 33.500-35.000 EPS. As a group, equities analysts predict that Eli Lilly and Company will post 23.48 EPS for the current year.

Eli Lilly and Company Increases Dividend

The company also recently declared a quarterly dividend, which will be paid on Tuesday, March 10th. Stockholders of record on Friday, February 13th will be paid a dividend of $1.73 per share. This is an increase from Eli Lilly and Company’s previous quarterly dividend of $1.50. This represents a $6.92 annualized dividend and a dividend yield of 0.7%. The ex-dividend date is Friday, February 13th. Eli Lilly and Company’s payout ratio is 30.15%.

Trending Headlines about Eli Lilly and Company

Here are the key news stories impacting Eli Lilly and Company this week:

• Positive Sentiment: RBC Capital initiated coverage of LLY with an Outperform rating and $1,250 price target, citing Lilly’s obesity franchise as likely to dominate through 2030 — a vote of confidence that supports multiple‑year growth expectations. RBC Capital Initiates Eli Lilly (LLY), Cites Long-Term Leadership in Obesity Market
• Positive Sentiment: Detailed ACHIEVE‑3/Phase 3 results show oral orforglipron outperformed oral semaglutide on A1C and weight loss; Lilly has submitted filings in 40+ countries and is eyeing potential U.S. action for obesity in Q2 — this readout is the primary near‑term catalyst for revenue upside. Lilly’s oral GLP-1, orforglipron, delivered superior blood sugar control and weight loss
• Positive Sentiment: Local permits approved for a $77M expansion of Lilly’s Concord, NC manufacturing campus — a capacity investment that supports expected higher demand for GLP‑1 products and reduces execution risk from supply constraints. Eli Lilly plans $77M expansion of manufacturing campus in Concord
• Positive Sentiment: High‑profile endorsements and analyst upgrades — including Jim Cramer recommending Lilly over Novo and Guggenheim nudging its price target higher — are pushing investor sentiment toward Lilly as the GLP‑1 sector consolidates. Jim Cramer Recommends Eli Lilly over Novo Nordisk Guggenheim adjusts price target on Eli Lilly
• Neutral Sentiment: BofA and other brokers argue Novo Nordisk’s recent GLP‑1 list‑price moves shouldn’t materially dent Lilly’s U.S. franchise, tempering fears of a price war — this helps explain resilient analyst views despite industry noise. Eli Lilly (LLY) Seen Resilient as BofA Downplays Novo Nordisk GLP-1 Price Impact
• Neutral Sentiment: Reuters and other outlets published additional safety/side‑effect details from the orforglipron diabetes trial — important for regulatory review but not showing any immediate red flags that would derail approval plans. Eli Lilly reports additional data on weight-loss pill from diabetes trial
• Negative Sentiment: Industry pricing pressure from Novo’s recent GLP‑1 list‑price cuts remains a potential headwind for gross‑to‑net and pricing dynamics; if rivals deepen price competition, margin expansion could be constrained over time. Eli Lilly stock down as Novo cuts GLP-1 prices

Analyst Ratings Changes

Several equities research analysts have recently issued reports on LLY shares. Truist Financial restated a “buy” rating on shares of Eli Lilly and Company in a report on Monday. UBS Group reissued a “buy” rating on shares of Eli Lilly and Company in a research report on Monday, February 2nd. Freedom Capital upgraded Eli Lilly and Company from a “hold” rating to a “strong-buy” rating in a research report on Tuesday, February 10th. Bank of America cut their target price on Eli Lilly and Company from $1,286.00 to $1,268.00 and set a “buy” rating on the stock in a research note on Monday, December 15th. Finally, Leerink Partners increased their price target on Eli Lilly and Company from $1,234.00 to $1,296.00 and gave the stock an “outperform” rating in a report on Thursday, February 5th. Two research analysts have rated the stock with a Strong Buy rating, twenty-three have given a Buy rating and five have assigned a Hold rating to the company’s stock. Based on data from MarketBeat, the company has an average rating of “Moderate Buy” and an average price target of $1,229.59.

Eli Lilly and Company Profile

Eli Lilly and Company (NYSE: LLY) is a global pharmaceutical company founded in 1876 and headquartered in Indianapolis, Indiana. The company researches, develops, manufactures and commercializes a broad range of medicines and therapies for patients worldwide. Eli Lilly maintains operations and commercial presence across North America, Europe, Asia and other regions, serving both developed and emerging markets. The company has been led in recent years by President and Chief Executive Officer David A.